1. Continuous glucose monitoring profile in COVID-19 patients with and without diabetes receiving methylprednisolone
- Author
-
He, Xingxing, Duan, Guangchen, Lu, Jingyi, Wang, Yaxin, Cai, Jinghao, Tong, Yiqing, Wu, Wei, Ma, Xiaojing, Feng, Qiming, and Zhou, Jian
- Abstract
Purpose: Methylprednisolone is widely used during the COVID-19 epidemic. We aimed to evaluate the glucose profile of COVID-19 patients with and without diabetes receiving methylprednisolone. Methods: 36 patients with COVID-19 admitted to hospital were included: 17 with and 19 without diabetes. Methylprednisolone 40 mg was administered at about 9:00 a.m. Glucose levels were assessed by blinded intermittently scanned continuous glucose monitoring (isCGM) for an average of 6.8 ± 2.4 days. Excess hyperglycemia was defined as time above range (TAR) > 10.0 mmol/L (TAR
>10.0 ) ≥ 25%, or TAR > 13.9 mmol/L (TAR>13.9 ) ≥ 10%. Results: Glucose management indicator (GMI) was significantly higher than the admission glycated hemoglobin A1c (HbA1c ) level in patients without diabetes [6.7 (6.1–7.0) % vs. 5.9 (5.9–6.1) %, P< 0.001], while no significant difference was found in patients with diabetes [9.0 (7.5–9.5) % vs. 8.9 (7.5–10.2) %, P> 0.05]. The difference between GMI and HbA1c (∆GMI-HbA1c ) in patients without diabetes was significantly higher than in patients with diabetes [0.7 (0.2–1.0) % vs. −0.2 (−1.5–0.5) %, P= 0.005]. The circadian patterns of glucose were similar in the two groups. In patients without diabetes, excess hyperglycemia occurred in 31.6% (6/19) of participants, with 31.6% (6/19) having a TAR>10.0 ≥ 25%, while 21.1% (4/19) had a TAR>13.9 ≥ 10%. Conclusion: The impact of methylprednisolone on glycemia was more pronounced in COVID-19 patients without diabetes, compared to those with diabetes. A significant burden of methylprednisolone-induced hyperglycemia was observed in patients without diabetes. Graphical Abstract:- Published
- 2024
- Full Text
- View/download PDF